Immorta Bio Inc.

https://www.immortabio.com/

Immorta Bio Inc. is a privately held biotechnology company headquartered in Miami Beach, Florida, dedicated to the research, development, and commercialization of therapeutic platforms. The company's core mission is to radically extend healthy human lifespan by targeting the biological root causes of aging and age-related diseases, operating under the philosophy of "Treating Diseases of Aging and Treating Aging as Disease™".

Immorta Bio is advancing a pipeline of senescence immunotherapies and personalized stem cell treatments through two primary platforms. SenoVax™ is a first-in-class senolytic immunotherapy designed to identify and eliminate senescent cells, which are implicated in cancer and other age-related pathologies, thereby restoring immune surveillance and promoting regeneration. Complementing this, StemCellRevivify™ is a personalized stem-cell-based rejuvenation platform that utilizes personalized Mesenchymal Stem Cells (pMSCs) and Personalized Progenitor Cells (PPCs) to restore regenerative capacity, aiming for organ repair, vascular regeneration, and immune balancing tailored to individual patient biology. These platforms target market segments including longevity, cancer, organ failure, neurodegeneration, and inflammatory diseases.

Led by Chairman & CEO Dr. Boris N. Reznik and President & CSO Dr. Thomas E. Ichim, Immorta Bio is currently in the preclinical stage of development. Recent notable developments include its selection for NYU Stern's prestigious Endless Frontier Labs 2026-27 Life Sciences Cohort in September 2026, an initiative aimed at accelerating its path to human clinical trials. The company also announced breakthrough preclinical results in March 2026, demonstrating dramatic lifespan extension in aging mouse models using its dual-platform therapeutic strategy. In May 2024, Immorta Bio reported a significant breakthrough in the treatment of liver failure with its PMSC-11 stem cell therapy, leading to a patent filing. The company has also expanded its leadership and governance, appointing Dr. Armin Rath as Chief Business Officer in July 2025 and former Ernst & Young Health Sciences Partner Howard Brooks to its Corporate Board of Directors in May 2026.

Latest updates

CID: 9645